CD8A and neoplasm: CD4+ T cells can bind to the non-polypeptide domain of MHC class II molecules, take part in T cell antigen receptor (TCR) signal transduction, and then initiate the differentiation of CD8+ T cells into cytotoxic T lymphocytes (CTL), maintaining and enhancing CTL’s anti-tumor response.